News tagged with docetaxel
Scientists at the Johns Hopkins Kimmel Cancer Center, working with Danish researchers, have developed a novel anticancer drug designed to travel -- undetected by normal cells -- through the bloodstream until activated by ...
Cancer Jul 09, 2012 | 5 / 5 (18) | 2 |
The power of taxane-based chemotherapy drugs are misunderstood and potentially underestimated, according to researchers at Weill Cornell Medical College in the September 15 issue of the journal Cancer Research.
Cancer Sep 17, 2012 | not rated yet | 0
Survival for advanced stomach and oesophagael cancer patients increases by 40 per cent when treated with the chemotherapy drug, Docetaxel – providing evidence to prescribe it as a second-line treatment, ...
Cancer Jan 23, 2013 | 5 / 5 (1) | 0
Results of a phase 3 trial published in The Lancet Oncology have confirmed that the drug abiraterone acetate (marketed as Zytiga) offers a significant survival benefit to patients with castration-resistant prostate cancer ...
Cancer Sep 17, 2012 | not rated yet | 0
Biomarkers which could help to predict resistance to chemotherapy in breast cancer patients have been identified by researchers from the University of Hull, UK.
Cancer Apr 12, 2012 | 5 / 5 (1) | 0
(HealthDay)—The U.S. Food and Drug Administration has approved the drug tbo-filgrastim to treat certain cancer patients undergoing chemotherapy who have a condition called severe neutropenia, the FDA said in a news release.
Medications Aug 30, 2012 | not rated yet | 0
(HealthDay) -- For men with metastatic castration-resistant prostate cancer (mCRPC), the addition of bevacizumab (B) to docetaxel plus prednisone (DP) is not associated with improved overall survival (OS), ...
Cancer Mar 27, 2012 | not rated yet | 0
(HealthDay) -- For patients with operable breast cancer, peripheral neuropathy due to adjuvant taxane therapy does not correlate with improved outcomes, according to research published online July 30 in the ...
Cancer Aug 02, 2012 | not rated yet | 0
A new study by an international team of investigators led by Dana-Farber Cancer Institute scientists is the first to demonstrate that chemotherapy and a new, targeted therapy work better in combination than chemotherapy alone ...
Cancer Nov 28, 2012 | not rated yet | 0 |
A new method of delivering cancer drugs that could cut down on chemotherapy's side effects and boost the strength of the tumor-fighting medicine has shown promise, US researchers said Wednesday.
Cancer Apr 04, 2012 | not rated yet | 0
(Medical Xpress)—Researchers at the Moffitt Cancer Center have found that delayed tumor growth and enhanced survival of mice bearing melanoma were possible by blocking the reconstitution of myeloid-derived suppressor cells ...
Immunology Dec 11, 2012 | 5 / 5 (2) | 0 |
More than half of all patients with ovarian cancer experience recurrent disease and will eventually fail to respond to chemotherapy. The failure of chemotherapy is usually due to the development of resistance to the two main ...
Cancer Nov 29, 2012 | not rated yet | 0
(HealthDay)—Anticoagulant use is associated with improved overall survival in men receiving docetaxel chemotherapy for treatment of metastatic castration-resistant prostate cancer (mCRPC), according to ...
Cancer Feb 19, 2013 | not rated yet | 0
The results of a new phase III trial show that crizotinib, a targeted therapy, is a more effective treatment than standard chemotherapy for patients with advanced, ALK-positive lung cancer, researchers said at the ESMO 2012 ...
Cancer Sep 30, 2012 | not rated yet | 0
Adding the monoclonal antibody bavituximab to docetaxel chemotherapy doubles overall response rate and improves progression-free survival and overall survival in late-stage non-squamous, non-small cell lung cancer (NS-NSCLC) ...
Cancer Sep 06, 2012 | 5 / 5 (2) | 0
Docetaxel (as generic or with trade name Taxotere) is a clinically well established anti-mitotic chemotherapy medication (that is, it interferes with cell division). It is used mainly for the treatment of breast, ovarian, prostate, and non-small cell lung cancer. Docetaxel has an FDA approved claim for treatment of patients who have locally advanced, or metastatic breast or non small-cell lung cancer who have undergone anthracycline-based chemotherapy and failed to stop cancer progression or relapsed. and a European approval for use in hormone-refractory prostate cancer.
According to a 2005 article in the journal Drugs, docetaxel administered as a one-hour infusion every three weeks generally over a ten cycle course, docetaxel is considered as or more effective than doxorubicin, paclitaxel and fluorouracil as a cytotoxic antimicrotubule agent.[dubious – discuss] However the effectiveness of Docetaxel vs. Paclitaxel and other taxenes is still controversial. Several more recent articles have found "no evidence that regimens containing docetaxel yield greater benefits than those including paclitaxel." Additionally, the optimal scheduling of docetaxel and other taxenes remains unconfirmed. A three-week administration schedule used to be and is still considered effected but new studies are indicating a weekly schedule might be better. A 2010 article in Current Clinical Pharmacology states, "weekly administration has emerged as the optimal schedule." Docetaxel is marketed worldwide under the name Taxotere by Sanofi-Aventis. Annual sales in 2010 were Euro 2.122 billion ($US 3.1 billion). Patent expired in 2010.
For more information about Docetaxel, read the full article at
This text uses material from Wikipedia and is available under the GNU Free Documentation License.